"Triastek" Partners with World's Largest Private Pharmaceutical Company: 3D Printing Technology Accelerates New Drug R&D | Yunqi Tech π

Triastek, a global leader in 3D-printed pharmaceuticals, operates a dual business model built around both proprietary product development and partnership-based drug development. The company has built proprietary end-to-end capabilities spanning pharmaceutical dosage form design, digital development, and continuous manufacturing.

Recently, Triastek entered into a collaboration agreement with Boehringer Ingelheim China, the world's largest privately held pharmaceutical company. The two parties will work together on rapid formulation development for new drug molecules.

In this edition of Yunqi Tech π, we bring you the latest on Triastek, a Yunqi Capital Series A+ portfolio company.

➤➤➤ Recently, Triastek (full name: Nanjing Triastek Pharmaceutical Technology Co., Ltd.) and Boehringer Ingelheim China signed a collaboration agreement. The partnership aims to explore applications of 3D printing technology in accelerating the development of new chemical entity (NCE) drug formulations.

Led by Boehringer Ingelheim China's Drug Development department, the collaboration will focus on rapid formulation development for new drug molecules. Triastek will leverage its MED® 3D printing technology for structural design of pharmaceutical formulations, developing multiple prototype formulations to explore dose design and release profiles of new chemical compounds — with the goal of improving both the speed and success rate of new drug development.

Founded in 1885, Boehringer Ingelheim is a pharmaceutical company dedicated to human biopharmaceuticals and animal health products, and is the world's largest privately held pharmaceutical enterprise.

This marks Triastek's first formal collaboration with Boehringer Ingelheim. In 2021, Triastek was selected for Boehringer Ingelheim's global opnMe program, where it applied MED® technology to solubility enhancement research for poorly soluble drugs, achieving in vitro dissolution enhancement and improved bioavailability in animal studies. That project was successfully completed.

Triastek positions itself as a platform company for 3D-printed pharmaceutical technology. Its proprietary MED® 3D printing technology is a versatile solid-dosage-form patent technology applicable not only to small-molecule drug development, but also with potential for oral delivery of large-molecule drugs. It covers digital pharmaceutical dosage form design and development as well as continuous manufacturing, enabling the company to provide partners with end-to-end technical solutions spanning drug research, development, and production, together with robust product patent protection strategies.

Dr. Jun Lu, Head of Drug Development at Boehringer Ingelheim China, said: "We are delighted to partner with Triastek to explore innovative applications of 3D printing technology in accelerating new drug development. We look forward to this collaboration demonstrating the value of 3D printing in pharmaceutical R&D, building greater confidence for both parties, and deepening our partnership to empower drug development at Boehringer Ingelheim China and globally — ultimately benefiting patients."

Dr. Senping Cheng, Founder and CEO of Triastek, said: "The formal collaboration between Triastek and Boehringer Ingelheim to explore the value of MED® 3D printing technology in new drug development will promote the adoption of emerging technologies in the pharmaceutical industry, improve the efficiency of new product development, and help clinically valuable drugs reach patients sooner."